Hyperprolactinemia and medications for bipolar disorder: Systematic review of a neglected issue in clinical practice

European Neuropsychopharmacology

Volumn 25, Issue 8, 2015, Pages 1045-1059

  Pacchiarotti, Isabella ^a   Murru, Andrea ^a   Kotzalidis, Georgios D ^b   Bonnin, C Mar ^a   Mazzarini, Lorenzo ^b   Colom, Francesc ^a   Vieta, Eduard ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Antidepressants; Antipsychotics; Bipolar disorder; Hyperprolactinemia; Mood stabilizers

Indexed keywords

AMFEBUTAMONE; ARIPIPRAZOLE; ASENAPINE; LAMOTRIGINE; LITHIUM; LITHIUM CARBONATE; LURASIDONE; MIRTAZAPINE; OLANZAPINE; PALIPERIDONE; PROLACTIN; QUETIAPINE; RISPERIDONE; VALPROIC ACID; ZIPRASIDONE; NEUROLEPTIC AGENT;

BIPOLAR DISORDER; CLINICAL PRACTICE; COCHRANE LIBRARY; ELECTROCONVULSIVE THERAPY; EMBASE; HUMAN; HYPERPROLACTINEMIA; MEDLINE; MENTAL PATIENT; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; REVIEW; SYSTEMATIC REVIEW; BLOOD; CHEMICALLY INDUCED; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; HUMANS; HYPERPROLACTINEMIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84938749650     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2015.04.007     Document Type: Review

References (88)

1. Adler C.M., Fleck D.E., Brecher M., Strakowski S.M. Safety and tolerability of quetiapine in the treatment of acute mania in bipolar disorder. J. Affect. Disord. 2007, 100(Suppl. 1):S15-S22.
2. Apud J.A., Cocchi D., Locatelli V., Masotto C., Müller E.E., Racagni G. Biochemical and functional aspects on the control of prolactin release by the hypothalamo-pituitary GABAergic system. Psychoneuroendocrinology 1989, 14:3-17.
3. Baştürk M., Karaaslan F., Esel E., Sofuoğlu S., Tutuş A., Yabanoğlu I. Effects of short and long-term lithium treatment on serum prolactin levels in patients with bipolar affective disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 2001, 25:315-322.
4. Berwaerts J., Lane R., Nuamah I.F., Lim P., Remmerie B., Hough D.W. Paliperidone extended-release as adjunctive therapy to lithium or valproate in the treatment of acute mania: a randomized, placebo-controlled study. J. Affect. Disord. 2011, 129:252-260.
5. Berwaerts J., Xu H., Nuamah I., Lim P., Hough D. Evaluation of the efficacy and safety of paliperidone extended-release in the treatment of acutemania: a randomized, double-blind, dose-response study. J. Affect. Disord. 2012, 136:e51-e60.
6. Berwaerts J., Melkote R., Nuamah I., Lim P. A randomized, placebo- and active-controlled study of paliperidone extended-release as maintenance treatment in patients with bipolar I disorder after an acute manic or mixed episode. J. Affect. Disord. 2012, 138:247-258.
7. Bishop J.R., Rubin L.H., Reilly J.L., Pavuluri M.N., Sweeney J.A. Risperidone-associated prolactin elevation and markers of bone turnover during acute treatment. Ther. Adv. Psychopharmacol. 2012, 2:95-102. 10.1177/2045125312442080.
8. Bowden C.L., Grunze H., Mullen J., Brecher M., Paulsson B., Jones M., Vågerö M., Svensson K A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J. Clin. Psychiatry 2005, 66:111-121.
9. Bowden C.L., Vieta E., Ice K.S., Schwartz J.H., Wang P.P., Versavel M. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial. J. Clin. Psychiatry 2010, 71:130-137.
10. Brown R., Taylor M.J., Geddes J. Aripiprazole alone or in combination for acute mania. Cochrane Database Syst. Rev. 2013, 12:CD005000.
11. 2 receptors. J. Pharmacol. Exp. Ther. 2002, 302:381-389.
12. Bushe C., Shaw M. Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics. J. Psychopharmacol. 2007, 21:768-773.
13. Bushe C.J., Bradley A., Pendlebury J. A review of hyperprolactinaemia and severe mental illness: are there implications for clinical biochemistry?. Ann. Clin. Biochem. 2010, 47:292-300.
14. Byerly M., Suppes T., Tran Q.V., Baker R.A. Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives. J. Clin. Psychopharmacol. 2007, 27:639-661.
15. 2 receptor is linked to reduced prolactin release. Int. J. Neuropsychopharmacol. 2012, 15:645-656.
16. Chaudhry H.R., Hofmann P., Loimer N., Kotter M., Quehenberger F., Fueger G. Prolactin and beta-endorphin serum elevations after ECT in manic patients. Acta Psychiatr. Scand. 2000, 102:386-389.
17. Chen S.T., Hsiao Y.L. Treatment with aripiprazole for hyperprolactinemia induced by pituitary microadenoma in a bipolar I disorder patient. J. Clin. Psychopharmacol. 2010, 30:78-80.
18. Coker F., Taylor D. Antidepressant-induced hyperprolactinaemia: incidence, mechanisms and management. CNS Drugs 2010, 24:563-574.
19. Cordes J., Kahl K.G., Werner C., Henning U., Regenbrecht G., Larisch R., Schmidt-Kraepelin C., Thünker J., Agelink M.W., Löffler S., Hohlfeld T., Gaebel W., Klimke A. Clomipramine-induced serum prolactin as a marker for serotonin and dopamine turnover: results of an open label study. Eur. Arch. Psychiatry Clin. Neurosci. 2011, 261:567-573.
20. de Bartolomeis A., Marmo F., Buonaguro E.F., Rossi R., Tomasetti C., Iasevoli F. Imaging brain gene expression profiles by antipsychotics: region-specific action of amisulpride on postsynaptic density transcripts com- pared to haloperidol. Eur. Neuropsychopharmacol. 2013, 23:1516-1529.
21. De Fruyt J., Deschepper E., Audenaert K., Constant E., Floris M., Pitchot W., Sienaert P., Souery D., Claes S. Second generation antipsychotics in the treatment of bipolar depression: a systematic review and meta-analysis. J. Psychopharmacol. 2012, 26:603-617.
22. De Hert M., Detraux J., Peuskens J. Second-generation and newly approved antipsychotics, serum prolactin levels and sexual dysfunctions: a critical literature review. Expert Opin. Drug. Saf. 2014, 13:605-624.
23. Dodge J.C., Badura L.L. Noradrenergic regulation of prolactin secretion at the level of the paraventricular nucleus of the hypothalamus: functional significance of the alpha-1b and beta-adrenergic receptor subtypes. Brain Res. 2004, 1016:240-246.
24. El Khoury A., Tham A., Mathé A.A., Aberg-Wistedt A., Stain-Malmgren R. Decreased plasma prolactin release in euthymic lithium-treated women with bipolar disorder. Neuropsychobiology 2003, 48:14-18.
25. Emiliano A.B., Fudge J.L. From galactorrhea to osteopenia: rethinking serotonin-prolactin interactions. Neuropsychopharmacology 2004, 29:833-846.
26. Geller B., Luby J.L., Joshi P., Wagner K.D., Emslie G., Walkup J.T., Axelson D.A., Bolhofner K., Robb A., Wolf D.V., Riddle M.A., Birmaher B., Nusrat N., Ryan N.D., Vitiello B., Tillman R., Lavori P. A randomized controlled trial of risperidone, lithium, or divalproex sodium for initial treatment of bipolar I disorder, manic or mixed phase, in children and adolescents. Arch. Gen. Psychiatry 2012, 69:515-528.
27. Gentile S. Adverse effects associated with second-generation antipsychotic long-acting injection treatment: a comprehensive systematic review. Pharmacotherapy 2013, 33:1087-1106.
28. Gladigau E.L., Fazio T.N., Hannam J.P., Dawson L.M., Jones S.G. Increased cardiovascular risk in patients with severe mental illness. Intern. Med. J. 2014, 44:65-69.
29. Grande I., Bernardo M., Bobes J., Saiz-Ruiz J., Álamo C., Vieta E. Antipsychotic switching in bipolar disorders: a systematic review. Int. J. Neuropsychopharmacol. 2014, 17:497-507.
30. Grunze H., Vieta E., Goodwin G.M., Bowden C., Licht R.W., Möller H.J., Kasper S., WFSBP Task Force on Treatment Guidelines for Bipolar Disorders The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder. World. J. Biol. Psychiatry 2013, 14:154-219.
31. Haddad P.M., Wieck A. Antipsychotic-induced hyperprolactinemia: mechanisms, clinical features and management. Drugs 2004, 64:2291-2314.
32. Haskett RF. Electroconvulsive therapy's mechanism of action: neuroendocrine hypotheses. J. ECT. 2014, 30:107-110. 10.1097/YCT.0000000000000143.
33. Jain S.K., Zelena D. Role of ionotropic glutamate receptors in the control of prolactin secretion by other neurotransmitters and neuropeptides at the level of the pituitary. Endocr. Regul. 2013, 47:65-74.
34. Kapur S., Langlois X., Vinken P., Megens A.A., De Coster R., Andrews J.S. The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats. J. Pharmacol. Exp. Ther. 2002, 302:1129-1134.
35. Keck P.E., Marcus R., Tourkodimitris S., Ali M., Liebeskind A., Saha A., Ingenito G., Aripiprazole Study Group A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am. J. Psychiatry 2003, 160:1651-1658.
36. Keck P.E., Orsulak P.J., Cutler A,J., Sanchez R., Torbeyns A., Marcus R.N., McQuade R.D., Carson W.H., CN138-135 Study Group Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study. J. Affect. Disord. 2009, 112:36-49.
37. Knegtering R., Baselmans P., Castelein S., Bosker F., Bruggeman R., van den Bosch R.J. Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels. Am. J. Psychiatry 2005, 162:1010-1012.
38. Kusalic M., Engelsmann F. Effect of lithium maintenance treatment on hypothalamic pituitary gonadal axis in bipolar men. J. Psychiatry Neurosci. 1996, 21:181-186.
39. Lanng Nielsen J., Amdisen A., Darling S., Pedersen E.B. Plasma prolactin during lithium treatment. Neuropsychobiology 1977, 3:30-34.
40. Leucht S., Cipriani A., Spineli L., Mavridis D., Orey D., Richter F., Samara M., Barbui C., Engel R.R., Geddes J.R., Kissling W., Stapf M.P., Lässig B., Salanti G., Davis J.M. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013, 382:951-962.
41. Loebel A., Cucchiaro J., Silva R., Kroger H., Sarma K., Xu J., Calabrese J.R. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am. J. Psychiatry 2014, 171:169-177.
42. Loebel A., Cucchiaro J., Silva R., Kroger H., Hsu J., Sarma K., Sachs G. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am. J. Psychiatry 2014, 171:160-168.
43. Lykouras L., Markianos M., Hatzimanolis Y. Prolactin and cortisol responses to acute intravenous clomipramine challenge in patients with mania, depression and healthy controls: evidence for reduced serotonergic responsivity. Neuropsychobiology 2011, 63:77-81.
44. Marder S.R., McQuade R.D., Stock E., Kaplita S., Marcus R., Safferman A.Z., Saha A., Ali M., Iwamoto T. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr. Res. 2003, 61:123-136.
45. McElroy S.L., Keck P.E. Metabolic syndrome in bipolar disorder: a review with a focus on bipolar depression. J. Clin. Psychiatry 2014, 75:46-61.
46. McIntyre R.S., Brecher M., Paulsson B., Huizar K., Mullen J. Quetiapine or haloperidol as monotherapy for bipolar mania-a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial. Eur. Neuropsychopharmacol. 2005, 15:573-585.
47. McIntyre R.S., Cohen M., Zhao J., Alphs L., Macek T.A., Panagides J. A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disord. 2009, 11:673-686. 10.1111/j.1399-5618.2009.00748.x.
48. McIntyre R.S., Cohen M., Zhao J., Alphs L., Macek T.A., Panagides J. Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study. J. Affect. Disord. 2010, 126:358-365.
49. Moeller O., Hetzel G., Michael N., Rothermundt M., Arolt V., Erfurth A. Basal prolactin values correlate with response to reboxetine treatment in major depression, but not with response to citalopram. Neuropsychobiology 2005, 51:67-71.
50. Moher D., Liberati A., Tetzlaff J., Altman D.G., PRISMA Group Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009, 6:e1000097.
51. Möller H.J. Amisulpride: limbic specificity and the mechanism of antipsychotic atypicality. Prog. Neuropsychopharmacol. Biol. Psychiatry 2003, 27:1101-1111.
52. Mornex R., Jordan D. Serotonin and endocrine rhythms. Biomedicine 1980, 32:163-165.
53. Murru A., Bernardo M., Bobes J., Saiz-Ruiz J., Álamo C., Vieta E. Antipsychotic switching in schizoaffective disorder: a systematic review. World J. Biol. Psychiatry 2015, 9:1-19.
54. Muzina D.J., Momah C., Eudicone J.M., Pikalov A., McQuade R.D., Marcus R.N., Sanchez R., Carlson B.X. Aripiprazole monotherapy in patients with rapid-cycling bipolar I disorder: an analysis from a long-term, double-blind, placebo-controlled study. Int. J. Clin. Pract. 2008, 62:679-687. 10.1111/j.1742-1241.2008.01735.x.
55. Pacchiarotti I., Bond D.J., Baldessarini R.J., Nolen W.A., Grunze H., Licht R.W., Post R.M., Berk M., Goodwin G.M., Sachs G.S., Tondo L., Findling R.L., Youngstrom E.A., Tohen M., Undurraga J., González-Pinto A., Goldberg J.F., Yildiz A., Altshuler L.L., Calabrese J.R., Mitchell P.B., Thase M.E., Koukopoulos A., Colom F., Frye M.A., Malhi G.S., Fountoulakis K.N., Vázquez G., Perlis R.H., Ketter T.A., Cassidy F., Akiskal H., Azorin J.M., Valentí M., Mazzei D.H., Lafer B., Kato T., Mazzarini L., Martínez-Aran A., Parker G., Souery D., Ozerdem A., McElroy S.L., Girardi P., Bauer M., Yatham L.N., Zarate C.A., Nierenberg A.A., Birmaher B., Kanba S., El-Mallakh R.S., Serretti A., Rihmer Z., Young A.H., Kotzalidis G.D., MacQueen G.M., Bowden C.L., Ghaemi S.N., Lopez-Jaramillo C., Rybakowski J., Ha K., Perugi G., Kasper S., Amsterdam J.D., Hirschfeld R.M., Kapczinski F., Vieta E. The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am. J. Psychiatry 2013, 170:1249-1262.
56. Papageorgiou A., Denef C. Estradiol induces expression of 5-hydroxytryptamine (5-HT) 4, 5-HT5, and 5-HT6 receptor messenger ribonucleic acid in rat anterior pituitary cell aggregates and allows prolactin release via the 5-HT4 receptor. Endocrinology 2007, 148:1384-1395.
57. Papakostas G.I., Miller K.K., Petersen T., Sklarsky K.G., Hilliker S.E., Klibanski A., Fava M. Serum prolactin levels among outpatients with major depressive disorder during the acute phase of treatment with fluoxetine. J. Clin. Psychiatry 2006, 67:952-957.
58. Perlis R.H., Welge J.A., Vornik L.A., Hirschfeld R.M., Keck P.E. Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials. J. Clin. Psychiatry 2006, 67:509-516.
59. Peuskens J., Pani L., Detraux J., De Hert M. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs 2014, 28:421-453.
60. Peveler R.C., Branford D., Citrome L., Fitzgerald P., Harvey P.W., Holt R.I., Howard L., Kohen D., Jones I., O'Keane V., Pariente C.M., Pendlebury J., Smith S.M., Yeomans D. Antipsychotics and hyperprolactinaemia: clinical recommendations. J. Psychopharmacol. 2008, 22:98-103.
61. Porter T.E., Grandy D., Bunzow J., Wiles C.D., Civelli O., Frawley L.S. Evidence that stimulatory dopamine receptors may be involved in the regulation of prolactin secretion. Endocrinology 1994, 134:1263-1268.
62. Rettenbacher M.A., Hofer A., Ebenbichler C., Baumgartner S., Edlinger M., Engl J., Kaser S., Kemmler G., Malik P., Tschoner A., Fleischhacker W.W. Prolactin levels and sexual adverse effects in patients with schizophrenia during antipsychotic treatment. J. Clin. Psychopharmacol. 2010, 30:711-715.
63. Rittenhouse P.A., Levy A.D., Li Q., Bethea C.L., Van de Kar L.D. Neurons in the hypothalamic paraventricular nucleus mediate the serotonergic stimulation of prolactin secretion via 5-HT1C/2 receptors. Endocrinology 1993, 133:661-667.
64. Robertson A.G., Berry R., Meltzer H.Y. Prolactin stimulating effects of amoxapine and loxapine in psychiatric patients. Psychopharmacology 1982, 78:287-292.
65. Sachs G.S., Vanderburg D.G., Edman S., Karayal O.N., Kolluri S., Bachinsky M., Cavus I. Adjunctive oral ziprasidone in patients with acute mania treated with lithium or divalproex, part 1: results of a randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 2012, 73:1412-1419.
66. Sagud M., Pivac N., Mück-Seler D., Jakovljević M., Mihaljević-Peles A., Korsić M. Effects of sertraline treatment on plasma cortisol, prolactin and thyroid hormones in female depressed patients. Neuropsychobiology 2002, 45:139-143.
67. Saie D.J., Sills E.S. Hyperprolactinemia presenting with encephalomalacia-associated seizure disorder and infertility: a novel application for bromocriptine therapy in reproductive endocrinology. Neuro Endocrinol. Lett. 2005, 26:533-535.
68. Sher L., Oquendo M.A., Li S., Ellis S., Brodsky B.S., Malone K.M., Cooper T.B., Mann J.J. Prolactin response to fenfluramine administration in patients with unipolar and bipolar depression and healthy controls. Psychoneuroendocrinology 2003, 28:559-573.
69. Schule C., Baghai T., Laakmann G. Mirtazapine decreases stimulatory effects of reboxetine on cortisol, adrenocorticotropin and prolactin secretion in healthy male subjects. Neuroendocrinology 2004, 79:54-62.
70. Sørensen H.J., Jensen S.O., Nielsen J. Schizophrenia, antipsychotics and risk of hip fracture: a population-based analysis. Eur. Neuropsychopharmacol. 2013, 23:872-878.
71. Tohen M., Kryzhanovskaya L., Carlson G., Delbello M., Wozniak J., Kowatch R., Wagner K., Findling R, Lin D., Robertson-Plouch C., Xu W., Dittmann R.W., Biederman J. Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am. J. Psychiatry 2007, 164:1547-1556.
72. Tohen M., Vieta E., Goodwin G.M., Sun B., Amsterdam J.D., Banov M., Shekhar A., Aaronson S.T., Bardenstein L., Grecu-Gabos I., Tochilov V., Prelipceanu D., Oliff H.S., Kryzhanovskaya L., Bowden C. Olanzapine versus divalproex versus placebo in the treatment of mild to moderate mania: a randomized, 12-week, double-blind study. J. Clin. Psychiatry 2008, 69:1776-1789.
73. 2A receptors stimulate ACTH, corticosterone, oxytocin, renin, and prolactin release and activate hypothalamic CRF and oxytocin-expressing cells. J. Neurosci. 2001, 21:3572-3579.
74. Veselinović T., Paulzen M., Gründer G. Cariprazine, a new, orally active dopamine D2/3 receptor partial agonist for the treatment of schizophrenia, bipolar mania and depression. Expert. Rev. Neurother. 2013, 13:1141-1159.
75. Vieta E. The bipolar maze: a roadmap through translational psychopathology. Acta Psychiatr. Scand. 2014, 129:323-327.
76. Vieta E. Antidepressants in bipolar I disorder: never as monotherapy. Am. J. Psychiatry 2014, 171:1023-1026. 10.1176/appi.ajp.2014.14070826.
77. Vieta E., Mullen J., Brecher M., Paulsson B., Jones M. Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double-blind, randomised, placebo-controlled studies. Curr. Med. Res. Opin. 2005, 21:923-934.
78. Vieta E., Ros S., Goikolea J.M., Benabarre A., Popova E., Comes M., Capapey J., Sánchez-Moreno J. An open-label study of amisulpride in the treatment of mania. J. Clin. Psychiatry 2005, 66:575-578.
79. Vieta E., Bourin M., Sanchez R., Marcus R., Stock E., McQuade R., Carson W., Abou-Gharbia N., Swanink R., Iwamoto T., Aripiprazole Study Group Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial. Br. J. Psychiatry 2005, 187:235-242.
80. Vieta E., Nuamah I.F., Lim P., Yuen E.C., Palumbo J.M., Hough D.W., Berwaerts J. A randomized, placebo- and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder. Bipolar Disord. 2010, 12:230-243.
81. Viktorin A., Lichtenstein P., Thase M.E., Larsson H., Lundholm C., Magnusson P.K., Landén M. The risk of switch to mania in patients with bipolar disorder during treatment with an antidepressant alone and in combination with a mood stabilizer. Am. J. Psychiatry 2014, 171:1067-1073. 10.1176/appi.ajp.2014.13111501.
82. Voicu V., Medvedovici A., Ranetti A.E., Rădulescu F.Ş. Drug-induced hypo- and hyperprolactinemia: mechanisms, clinical and therapeutic consequences. Expert. Opin. Drug. Metab. Toxicol. 2013, 9:955-968.
83. Willems E., Knigge U., Jorgensen H., Kjaer A., Warberg J. Effect of selective blockade of catecholaminergic alpha and beta receptors on histamine-induced release of corticotropin and prolactin. Neuroendocrinology 1999, 69:309-315.
84. Whiteford H.A., Degenhardt L., Rehm J., Baxter A.J., Ferrari A.J., Erskine H.E., Charlson F.J., Norman R.E., Flaxman A.D., Johns N., Burstein R., Murray C.J., Vos T. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet 2013, 382:1575-1586.
85. Wood A.J., Goodwin G.M. A review of the biochemical and neuropharmacological actions of lithium. Psychol. Med. 1987, 17:579-600.
86. Yatham L.N. Prolactin and cortisol responses to fenfluramine challenge in mania. Biol. Psychiatry 1996, 39:285-288.
87. Young R.M., Lawford B.R., Barnes M., Burton S.C., Ritchie T., Ward W.K., Noble E.P. Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele. Br. J. Psychiatry 2004, 185:147-151.
88. Young A.H., Oren D.A., Lowy A., McQuade R.D., Marcus R.N., Carson W.H., Spiller N.H., Torbeyns A.F., Sanchez R. Aripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled study. Br. J. Psychiatry 2009, 194:40-48.